Moderna Inc

Sivik Global Healthcare LLC has acquired a new position in Moderna (NASDAQ:MRNA), purchasing 10,000 shares valued at approximately $1.93 million, making it 1.2% of their portfolio. Despite this new investment, analysts generally maintain a "Hold" rating with an average price target significantly below the current trading price. The article also notes recent insider selling by Moderna executives and highlights both potential upside from new vaccine developments and ongoing valuation concerns.

Moderna's stock (MRNA) recently gained over $4 billion due to optimism around its personalized mRNA-based cancer therapy, intismeran autogene, and its inclusion in the Nasdaq-100 Index. While these are positive catalysts, the company's long-term success depends on advancing its pipeline and achieving commercial success. Despite a significant year-to-date rally and a premium valuation, long-term investors may consider holding due to evolving growth opportunities in oncology and respiratory vaccines, but short-term investors might find better entry points later.

UnitedHealth Group (UNH) shares rose over 4% after the company reported better-than-expected earnings for the third quarter of 2026 and raised its full-year earnings outlook to at least $20.50 per share. The health insurance giant's adjusted earnings per share were $4.69 on $112.69 billion in revenue, surpassing analyst expectations. Despite recent concerns about Medicare Advantage star ratings, the stock's year-to-date gains now stand at approximately 17%.

Noubar Afeyan, co-founder of Moderna, is advocating for the regulation of commercially sold AI agents, drawing parallels to the thalidomide tragedy to emphasize the need for pre-market safety verification. He suggests that regulation should focus on companies developing AI agents rather than large language models, viewing agents as having "intentionality." This stance aligns him with other tech leaders concerned about the increasing capabilities and independence of AI systems, especially following recent incidents involving Anthropic's Claude AI models.

TuHURA Biosciences announced it has received a new U.S. patent for its VISTA-inhibiting antibody, TBS-2025, titled "Anti-VISTA Antibodies and Uses Thereof." This patent expands intellectual property coverage for TBS-2025, including various molecular modifications and therapeutic applications beyond cancer, such as autoimmune diseases and infections, and runs until February 2042. The company is currently conducting clinical trials for TBS-2025 in acute myeloid leukemia and for its lead compound IFx-2.0 in Merkel Cell Carcinoma.

Moderna, Inc. announced that it will report its third-quarter 2026 financial results on Friday, November 6, 2026, through a live conference call and webcast at 8:00 a.m. ET. The event will also include a corporate update and will be accessible via the Investors section of Moderna's website. An archived webcast will be available for one year after the call.

Moderna, Inc. (NASDAQ: MRNA) announced it will host a live conference call and webcast on Friday, November 6, 2026, at 8:00 a.m. ET to discuss its third-quarter 2026 financial results and provide a corporate update. The webcast will be accessible through the Investors section of Moderna's website, with an archive available for one year.

Moderna shares recently saw an 18% gain, reaching a four-year high, following news of a planned public-private effort to accelerate cancer vaccine development and the company's inclusion in the Nasdaq-100 index. The stock has surged over 600% this year, driven by positive Phase 3 trial results for its mRNA cancer vaccine developed with Merck, with full data expected soon and regulatory approval anticipated next year. This success also led to significant gains for other vaccine developers like BioNTech and Novavax.

Moderna's recent surge due to promising cancer vaccine data has brought mRNA oncology into the investment spotlight. This article explores three companies—Moderna (MRNA), Arcturus Therapeutics Holdings (ARCT), and Vaxcyte (PCVX)—exposed to this trend, detailing their approaches to mRNA and vaccine development. It highlights the unique aspects and challenges each company faces, from Moderna's diversified pipeline to Arcturus's self-amplifying mRNA and Vaxcyte's focus on traditional vaccines.

Moderna Inc. (MRNA) shares dropped 5.73% on October 12, primarily due to investors taking profits after a significant recent rally driven by news of a potential NIH initiative for personalized mRNA cancer vaccines and the company's inclusion in the Nasdaq-100 Index. Despite enthusiasm for its oncology pipeline, Wall Street analysts maintain cautious price targets due to valuation friction, as the company remains unprofitable with high cash burn. The pullback also reflects persistent valuation discipline and underlying fundamental realities as Moderna transitions its product portfolio.